Radiologists bridge real-world imaging and research, key to tracking Alzheimer’s and evaluating new therapies through ALZ-NET data.
Ana M. Franceschi, MD
Ana M Franceschi, MD, Chair of the American College of Radiology Neuroradiology Research Committee, contributed this piece.
With the recent FDA approvals of novel therapies for Alzheimer's disease (AD), clinical practices are expecting to see an increase in volume of patients who may be candidates for these therapies. Subsequently, imaging referrals, particularly MRI and PET scans, will occur as clinicians seek to determine eligibility for the therapies and ensure ongoing safety monitoring. As the clinical landscape continues to evolve, radiology departments and facilities will need to adapt to these expected increases of neuroradiology volumes without compromising image quality and patient safety.
Clinical findings associated with AD therapies, particularly critical safety findings, should utilize standardized reporting to ensure consistent interpretability by treating clinicians. For example, early detection and accurate classification of Amyloid-Related Imaging Abnormalities (ARIA) are necessary for patient safety and clinical decision-making in AD care.
ARIA is a known complication in patients receiving anti-amyloid therapies in clinical trials and has also been reported in real-world research registries like the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET). However, ALZ-NET researchers are finding that there are real-world ARIA reporting inconsistencies, prompting concern for how findings are interpreted or escalated.
For this reason, it is imperative that radiologists are not only experts and educators of detection and appearance of ARIA, but champions for standardization of ARIA reporting with ARIA with Emerging AD Therapeutics templates. Radiologists, inclusive of neuroradiologists, and generalists in private practice and academic institutions, serve as drivers of systemic change and can lead to advancements in practice now.
In addition, radiologists reading brain scans for patients with AD are highly encouraged to serve as ambassadors for their imaging facilities and register for the ALZ-NET Imaging Network. When an imaging facility participates in ALZ-NET, they become part of the community of radiologists who are defining best practices.
What are the benefits of joining the ALZ-NET Imaging Network?
Participating imaging facilities assign an imaging staff member to upload DICOM studies for ALZ-NET participants in exchange for:
As novel therapies continue to emerge in the AD field, ALZ-NET will continue to promote the value of robust imaging datasets as a means of understanding the progression of disease and the benefit of the available therapies. A radiologist's role in AD science advancement is clear – they are architects of the bridge between real-world imaging and research that is essential for driving science-based clinical decision-making.
Advocacy to Access: Missouri’s Breast Screening Success
Radiology advocacy plays a key role in improving patient care, according to a new Neiman HPI study published in JACR.
Read more
#FocusedForwardTogether
Discussion of upcoming advocacy efforts taking place during the ACR 2025 annual meeting and how members can participate.
Read more
Lessons from Hurricane Helene and Beyond
Radiology as a profession has weathered countless storms in recent memory. The many unprecedented challenges of the COVID-19 years; seemingly endless CMS cuts and declining reimbursement in the face of soaring imaging volumes and workforce shortages; dangerous scope of practice expansion by unqualified individuals, and the increasingly prevalent corporate practice of medicine.
Read more
